Pluristem and NIAID Met With U.S. FDA and Agreed on Development Plan for Initiation of Pivotal Study of PLX-R18 in the Treatment of Acute Radiation Syndrome Print E-mail
By Staff and Wire Reports   
Monday, 21 September 2015 11:02
Pluristem Therapeutics Inc. (PSTI.TA) (PSTI.TA), a leading developer of placenta-based cell therapy products, announced today that Pluristem and the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), completed a successful meeting with the U.S. Food and Drug Administration (FDA) regarding the development program for PLX-R18 cells in the treatment of Acute Radiation Syndrome (ARS).
If Only Steve Jobs Had Known PharmaCyte and Biotech Cell-in-a-Box Print E-mail
By OTC   
Thursday, 17 September 2015 10:54
If only Steve Jobs had access to this therapy before Pancreatic Cancer took his life. Had he known of PharmaCyte Biotech's (PMCB) live-cell encapsulation technology then, he may still be with us.
GSK Lung Drug Fails to Meet Primary Goal in Clinical Trial Print E-mail
By Staff and Wire Reports   
Wednesday, 16 September 2015 12:39
GlaxoSmithKline’s Breo Ellipta failed to meet its primary goal in a pivotal clinical trial of curbing death risk in patients suffering from chronic pulmonary obstructive disease.
FDA Enforcement of Off-Label Promotion Hindered by Website, Lawsuit Print E-mail
By FDAnews Drug Daily Bulletin   
Tuesday, 15 September 2015 01:28
  FDA enforcement of drug companies’ use of off-label promotion is being made more difficult by Amarin’s successful lawsuit against the agency and by a government website,, a law professor says.
Orgenesis Featured in Special Report on Curing Diabetes Print E-mail
By CRWE Press Release   
Sunday, 13 September 2015 14:20
Orgenesis, Inc. (OTCQB:ORGS) and Scott Carmer the Company’s U.S. CEO, is featured in the Special Report: Curing Diabetes. To view the segment please visit:
CAR T-Cell Therapeutics: Alan Leong of BioWatch Looks Beyond the Buzz for Solid Early-Stage Plays Print E-mail
By Gail Dutton of The Life Sciences Report   
Wednesday, 09 September 2015 22:03
icon_newsmakersCAR T-cell therapies show amazing potential in treating blood cancers, but there's a lot of work to do before the cells are ready for commercialization. Alan Leong, senior analyst with BioWatch, tells The Life Sciences Report about the latest in CAR T-cell therapeutics and how some companies are hedging their bets by developing bispecific antibodies. He also describes the reality behind the growing excitement in regenerative medicine, and what investors should know about some very innovative, but often overlooked, small companies.
PDI Announces Additional Diagnostic Tests, Shares Off Session Highs Print E-mail
By Josh Gee   
Friday, 14 August 2015 18:20
PDI, Inc. (NASDAQ:PDII) subsidiary Interpace Diagnostics has confirmed that ThyGenX Thyroid Oncogene Panel as well as ThyraMIR are under the ambit of largest independent Blue Cross Blue Shield plans which insures over 3.3 million lives.   
Regenerative Medicine in Japan: CJ PARTNERS' Colin Lee Novick ATHX, RP, RGS, 7774:TYO, 4527:TYO, 2372:TYO Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 05 August 2015 18:15
Regenerative medicine is just beginning to be understood by governments and investors alike. Last autumn, new regulations took effect in Japan that promise to speed patient access to some of these new therapies.
Cantor Fitzgerald's Caroline Corner: Cutting-Edge Devices and Diagnostics Deliver Drugs and Profits Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 29 July 2015 17:13
Medical technology is not considered a huge-margin investment in the way that the biotech and drug industries are. However, some of today's medtech blurs the line, including hybrid companies developing stem cell and drug-device delivery systems that address complex disease indications ranging from blindness to spinal paralysis.
Play the Gap to Profit from Australia's Undervalued Biotech Gems: John Hester of Bell Potter Securities Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 22 July 2015 15:22
Investors who lament missing the U.S. biotech bull market might have another avenue to pursue. Biotech valuations in Australia are not in sync with U.S. biotech valuations, and comparable stocks from Down Under may have extraordinary technology platforms and huge upside potential. In this interview with The Life Sciences Report, Senior Healthcare Analyst John Hester of Bell Potter Securities discusses two hidden Australian biotech gems, one of which could ride the coattails of a U.S.-based product on a very positive regulatory path.
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 5 of 56